Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) traded down 0.6% on Tuesday after an insider sold shares in the company. The company traded as low as $66.13 and last traded at $72.65. 551,300 shares were traded during trading, an increase of 39% from the average session volume of 395,797 shares. The stock had previously closed at $72.25.
Specifically, CEO Jeffrey D. Marrazzo sold 20,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.54, for a total value of $1,430,800.00. Following the sale, the chief executive officer now owns 250,000 shares of the company’s stock, valued at approximately $17,885,000. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $81.00, for a total transaction of $445,500.00. Following the completion of the sale, the insider now directly owns 10,825 shares in the company, valued at approximately $876,825. The disclosure for this sale can be found here. In the last three months, insiders sold 1,099,659 shares of company stock worth $92,457,658. Insiders own 7.30% of the company’s stock.
ONCE has been the subject of several research analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a research report on Tuesday, October 10th. SunTrust Banks, Inc. set a $101.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th. Cowen and Company reaffirmed a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Royal Bank Of Canada dropped their target price on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Wednesday, November 8th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $111.00 target price on shares of Spark Therapeutics in a research report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $90.36.
A number of hedge funds and other institutional investors have recently made changes to their positions in ONCE. BlackRock Inc. grew its position in Spark Therapeutics by 11,332.0% during the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after buying an additional 1,824,117 shares during the period. Janus Henderson Group PLC bought a new stake in Spark Therapeutics during the second quarter valued at approximately $30,848,000. Orbimed Advisors LLC bought a new stake in Spark Therapeutics during the third quarter valued at approximately $38,340,000. Jennison Associates LLC bought a new stake in Spark Therapeutics during the third quarter valued at approximately $27,239,000. Finally, JPMorgan Chase & Co. grew its position in Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after buying an additional 241,016 shares during the period. Institutional investors own 77.94% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.